Age-related Macular Degeneration Market Growth, Size, Trends Analysis- By Product, By Molecules, By Type of AMD, By Approval Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Age-related Macular Degeneration Market Introduction and Overview

According to SPER Market Research, 'Global Age-related Macular Degenerations Market Size- By Product, By Molecules, By Type of AMD, By Approval Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' states that the Global Age-related Macular Degenerations Market is estimated to reach USD 26.34 billion by 2033 with a CAGR of 10.97%.

Age-related macular degeneration (AMD) is a degenerative eye disease that mainly affects the elderly. It is characterized by the degeneration of the macula, the central area of the retina that offers sharp, detailed vision. AMD, which can cause blurred or distorted vision and, in its more advanced stages, significant visual loss, can affect routine skills like reading and facial recognition.

The global market for age-related macular degeneration (AMD) is significantly impacted by the COVID-19 pandemic in a number of ways. Patients missed important consultations and follow-up care as a result of delays in routine eye exams and treatments brought on by interruptions in healthcare services. Because COVID-19 was frequently given priority over long-term illnesses like AMD, many persons had an increase in symptoms and a fall in detection rates.

Scope of the report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Product, By Molecules, By Type of AMD, By Approval Type, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Amgen Inc., Bausch Health Companies Inc., Bayer AG, Biogen, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Samsung Bioepis, Others.

Age-related Macular Degenerations Market Segmentation:

By Products: Based on the Products, Global Age-related Macular Degenerations Market is segmented as; Lucentis, Eylea & Eylea HD, Vabysmo, Sofovre, Others.

By Molecules: Based on the Molecules, Global Age-related Macular Degenerations Market is segmented as; Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Others.

By Type of AMD: Based on the Type of AMD, Global Age-related Macular Degenerations Market is segmented as; Wet AMD, Dry AMD.

By Approval Type: Based on the Approval Type, Global Age-related Macular Degenerations Market is segmented as; Biologic, Biosimilar.

Product Code: PHAR2412

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Age-related Macular Degeneration Market.

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Age-related Macular Degeneration Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Age-related Macular Degeneration Market

7. Global Age-related Macular Degeneration Market, By Products (USD Million) 2020-2033

7.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Products, 2020-2026
7.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Products, 2027-2033
7.3. Lucentis
7.4. Eylea & Eylea HD
7.5. Vabysmo
7.6. Sofovre
7.7. Others

8. Global Age-related Macular Degeneration Market, By Molecules (USD Million) 2020-2033

8.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Molecules, 2020-2026
8.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Molecules, 2027-2033
8.3. Ranibizumab
8.4. Aflibercept
8.5. Faricimab
8.6. Pegcetoplan
8.7. Others

9. Global Age-related Macular Degeneration Market, By Type of AMD (USD Million) 2020-2033

9.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Type of AMD, 2020-2026
9.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Type of AMD, 2027-2033
9.3. Wet AMD
9.4. Dry AMD

10. Global Age-related Macular Degeneration Market, By Approval Type (USD Million) 2020-2033

10.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Approval Type, 2020-2026
10.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Approval Type, 2027-2033
10.3. Biologic
10.4. Biosimilar

11. Global Age-related Macular Degeneration Market, By End User (USD Million) 2020-2033

11.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By End User, 2020-2026
11.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By End User, 2027-2033
11.3. Hospitals
11.4. Specialty Centers
11.5. Long-Term Care Facilities

12. Global Age-related Macular Degeneration Market Forecast, 2020-2033 (USD Million)

12.1. Global Age-related Macular Degeneration Market Size and Market Share

13. Global Age-related Macular Degeneration Market, By Region, 2020-2033 (USD Million)

13.1. Global Age-related Macular Degeneration Market Size and Market Share By Region (2020-2026)
13.2. Global Age-related Macular Degeneration Market Size and Market Share By Region (2027-2033)
13.3. Asia-Pacific
- 13.3.1. Australia
- 13.3.2. China
- 13.3.3. India
- 13.3.4. Japan
- 13.3.5. South Korea
- 13.3.6. Rest of Asia-Pacific
13.4. Europe
- 13.4.1. France
- 13.4.2. Germany
- 13.4.3. Italy
- 13.4.4. Spain
- 13.4.5. United Kingdom
- 13.4.6. Rest of Europe
13.5. Middle East and Africa
- 13.5.1. Kingdom of Saudi Arabia
- 13.5.2. United Arab Emirates
- 13.5.3. Qatar
- 13.5.4. South Africa
- 13.5.5. Egypt
- 13.5.6. Morocco
- 13.5.7. Nigeria
- 13.5.8. Rest of Middle-East and Africa
13.6. North America
- 13.6.1. Canada
- 13.6.2. Mexico
- 13.6.3. United States
13.7. Latin America
- 13.7.1. Argentina
- 13.7.2. Brazil
- 13.7.3. Rest of Latin America

14. Company Profile

14.1. Amgen Inc.
- 14.1.1. Company details
- 14.1.2. Financial outlook
- 14.1.3. Product summary
- 14.1.4. Recent developments
14.2. Bausch Health Companies Inc.
- 14.2.1. Company details
- 14.2.2. Financial outlook
- 14.2.3. Product summary
- 14.2.4. Recent developments
14.3. Bayer AG
- 14.3.1. Company details
- 14.3.2. Financial outlook
- 14.3.3. Product summary
- 14.3.4. Recent developments
14.4. Biogen
- 14.4.1. Company details
- 14.4.2. Financial outlook
- 14.4.3. Product summary
- 14.4.4. Recent developments
14.5. F. Hoffmann-La Roche Ltd
- 14.5.1. Company details
- 14.5.2. Financial outlook
- 14.5.3. Product summary
- 14.5.4. Recent developments
14.6. Novartis AG
- 14.6.1. Company details
- 14.6.2. Financial outlook
- 14.6.3. Product summary
- 14.6.4. Recent developments
14.7. Pfizer Inc.
- 14.7.1. Company details
- 14.7.2. Financial outlook
- 14.7.3. Product summary
- 14.7.4. Recent developments
14.8. Regeneron Pharmaceuticals Inc.
- 14.8.1. Company details
- 14.8.2. Financial outlook
- 14.8.3. Product summary
- 14.8.4. Recent developments
14.9. Samsung Bioepis
- 14.9.1. Company details
- 14.9.2. Financial outlook
- 14.9.3. Product summary
- 14.9.4. Recent developments
14.10. Others